Follistatin Research Information
Regulatory Glycoprotein
TGF-β Superfamily Antagonist for Muscle & Metabolic Research
Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
Contents
What is Follistatin?
Follistatin (FST) is a regulatory glycoprotein that functions as a potent neutralizer of members of the transforming growth factor-beta (TGF-β) superfamily, including activins and myostatin [citation:1][citation:5]. It is a monomeric secretory protein expressed in nearly all tissues at variable concentrations [citation:6].
The protein is composed of 344 residues with three successive Kazal-type serine protease inhibitor-like domains, also known as follistatin domains, that facilitate high-affinity binding interactions with TGF-β superfamily ligands [citation:1].
Isoforms
Multiple isoforms exist due to alternative mRNA splicing and post-translational processing [citation:1][citation:5]:
FST315
Main circulating isoform with acidic C-terminal tail. Primary form found in bloodstream, predominantly targeting muscle tissue [citation:1][citation:6]
FST288
Lacks acidic C-terminal domain. Greater cell surface affinity, acts in autocrine fashion. Involved in reproductive health [citation:5][citation:6]
FST303
Produced by proteolytic cleavage of the C-terminal tail domain. Gonad-specific isoform [citation:5][citation:6]
FST344
Most basic form, primarily used in gene therapy research. Post-translational modification yields FST315 [citation:6][citation:10]
Mechanism of Action
Follistatin functions through multiple pathways to support research models:
Myostatin Inhibition
Binds to and neutralizes myostatin (GDF8), a potent inhibitor of skeletal muscle growth [citation:5][citation:6]
Activin Neutralization
Inhibits activin-mediated signaling through competitive inhibition of binding to ActRIIB receptors [citation:6]
Broad TGF-β Modulation
Antagonizes multiple TGF-β superfamily members including GDFs and BMPs [citation:1]
Follistatin modulates the ability of TGF-β superfamily ligands to bind to their cognate cell surface receptors. FST288 conducts itself more in an autocrine fashion, while FST315 (primarily found in circulation) behaves as an endocrine factor [citation:5].
Research Applications
Muscle Research
Skeletal muscle hypertrophy, regeneration, muscular dystrophy, and muscle wasting models [citation:1][citation:5]
Inflammatory Pathways
Anti-inflammatory activity, wound healing, fibrosis research [citation:1][citation:6]
Reproductive Biology
Fertility research, activin-inhibin axis studies, gonad function [citation:6][citation:10]
Metabolic Research
Obesity, glucose tolerance, hepatic steatosis, adipocyte regulation [citation:9]
Clinical Studies
Key Research Findings:
- FST-transgenic mice produced robust skeletal muscle hypertrophy phenotype with 194-327% increase in muscle mass relative to controls [citation:6]
- Follistatin gene therapy improved ambulation in Becker muscular dystrophy clinical trial with no adverse effects on reproductive capacity [citation:6]
- Systemic FST315-ΔHBS-Fc administration increased body weight and lean muscle mass after weekly administration in normal mice [citation:5]
- FST treatment proved a potent inducer of muscle remodeling and regeneration, modulating early inflammatory phase [citation:5]
- Follistatin-derived peptide FS I-I showed decreased fat accumulation and resistance to high-fat diet-induced obesity [citation:9]
- Native FST315 exhibits rapid clearance kinetics; engineered variants showed ∼100-fold improvement in terminal half-life [citation:1]
Dosing Guide
Reconstitute 1mg vial with 3.0 mL bacteriostatic water = 0.333 mg/mL concentration.
Step 1: Select Vial Size
Step 2: Select Dose
Research protocols typically use 100-300mcg subcutaneously daily [citation:11]
Vial Size
1mg Vial
Selected Dose
100 mcg
Doses per Vial
10 doses
Units on Syringe
3 units
Volume
0.03 mL
Protocol
Standard
Recommended Schedule
Daily - Subcutaneous Injection
Do not change your dose unless advised by a qualified professional.
Reconstitution Instructions
Add 3.0 mL bacteriostatic water to your freeze-dried 1mg vial = 0.333 mg/mL concentration.
Vial Size
1mg vial with 3.0mL bac water (0.333 mg/mL)
| Dose | Units on Syringe | Volume (mL) | Protocol |
|---|
Always use a new sterile needle and syringe for each injection.
Safety & Precautions
Do not use if you:
- Are allergic to follistatin or any components
- Are pregnant or breastfeeding
Storage Instructions:
- Lyophilized: Store at -20°C (-4°F) long-term
- After reconstitution: Refrigerate at 2-8°C (35.6-46.4°F), use within 7-10 days
- Avoid freeze-thaw cycles after reconstitution
Warning: If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.
References
- Datta-Mannan A, et al. An Engineered Human Follistatin Variant. J Pharm Sci. 2025. doi:10.1016/j.xphs.2024.12.018 [citation:1]
- Yaden BC, et al. Follistatin: A Novel Therapeutic for the Improvement of Muscle Regeneration. J Pharm Sci. 2025. doi:10.1016/j.xphs.2024.11.009 [citation:5]
- Rodino-Klapac LR, et al. Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. J Neuromuscul Dis. 2015;2(1):47-60. doi:10.3233/JND-150083 [citation:6]
- Kimura F, et al. The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology. 2010;151(3):1310-1319. doi:10.1210/en.2009-1176 [citation:2]
- Nakatani M, et al. Follistatin-derived peptide FS I-I decreases fat accumulation. FASEB J. 2008;22(2):477-487. doi:10.1096/fj.07-9184com [citation:9]
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: August 2026